ELI LILLY SUBMITS SEC FILING FOR EIGHT-PART NOTES OFFERING WORTH UP TO $9 BILLION
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy LLY?
Source: moomoo
- Company Filing: Eli Lilly has filed for an offering of up to $9 billion in senior notes.
- Purpose of Offering: The proceeds from this offering are intended for general corporate purposes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 988.870
Low
950.00
Averages
1192
High
1500
Current: 988.870
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Reports Skyrocketing Q1 Profits Driven by GLP-1 Sales
- Revenue Surge: Eli Lilly's Q1 revenue soared 56% year-over-year to $19.8 billion, primarily driven by its blockbuster GLP-1 weight loss drugs, demonstrating robust market demand despite a 13% price decline offset by a 65% volume increase.
- Net Income Spike: Adjusted net income skyrocketed 155% to $7.7 billion, translating to $8.55 per share, significantly surpassing Wall Street's estimate of $6.79, reflecting the company's strong performance in the weight loss drug sector.
- Sales Growth Drivers: Sales of GLP-1 drugs Mounjaro and Zepbound surged 125% and 80%, reaching $8.7 billion and $4.2 billion respectively, becoming key growth drivers that further solidify the company's market leadership.
- Optimistic Outlook: Eli Lilly raised its 2023 revenue and adjusted EPS guidance to $82 billion to $85 billion and $35.50 to $37, indicating confidence in future growth, particularly with the newly launched GLP-1 pill Foundayo expected to expand market share.
See More
Health Canada Approves Lilly's Kisunla™ (Donanemab) as a New Treatment for Early Alzheimer's Disease
Health Canada Authorization: Health Canada has authorized the use of Lilly's drug, known as Skysunla (donanemab), for the treatment of early Alzheimer's disease.
New Treatment Option: This approval introduces a new therapeutic option aimed at addressing the needs of patients diagnosed with early-stage Alzheimer's.
See More
ELI LILLY SUBMITS SEC FILING FOR EIGHT-PART NOTES OFFERING WORTH UP TO $9 BILLION
- Company Filing: Eli Lilly has filed for an offering of up to $9 billion in senior notes.
- Purpose of Offering: The proceeds from this offering are intended for general corporate purposes.
See More
Eli Lilly Invests $4.5 Billion in Indiana for Advanced Therapies
- Facility Opening: Eli Lilly opened the Lilly Lebanon Advanced Therapies center in Indiana on Wednesday, focusing on genetic disease treatments, which is expected to significantly enhance its production capabilities in genetic medicine.
- Increased Capital Investment: The company announced an additional investment of $4.5 billion for the new facility, bringing its total investment in Indiana to $21 billion since 2020, reflecting strong confidence in future drug demand.
- API Production Plans: Lilly plans to open the Lilly Lebanon API facility by 2027, which will become the largest active pharmaceutical ingredient production site in U.S. history, further solidifying its leadership in the pharmaceutical industry.
- Positive Market Reaction: Despite LLY stock being down nearly 8% this year, it has risen about 28% over the past 12 months, with retail investors expressing an 'extremely bullish' sentiment, indicating market recognition of its investment strategy.
See More
Novo Nordisk CEO: Seeking More Deals to Broaden Pipeline
- Active Business Development: Novo Nordisk CEO Mike Doustdar stated that the company is actively seeking deals with other firms that have complementary assets to fulfill its ambition of helping hundreds of millions of patients, demonstrating its strategic commitment in the competitive obesity drug market.
- Market Competition Pressure: Although Novo Nordisk pioneered the GLP-1 weight loss drug market, rival Eli Lilly has surpassed it in market share for weekly GLP-1 injections, highlighting the challenges the company faces in maintaining its leadership position.
- Optimistic Pipeline Outlook: Doustdar expressed optimism about upcoming treatments, particularly mentioning CagriSema and zenagamtide, which are expected to receive approval by the end of the year, indicating Novo Nordisk's strong R&D capabilities within the industry.
- Increased Profit Guidance: Following better-than-expected performance of the Wegovy pill, Novo Nordisk raised its full-year profit guidance, reflecting the company's confidence in future performance, which may attract more investor interest.
See More
Novo Nordisk Actively Pursuing Acquisition Opportunities
- Market Leadership Challenges: CEO Mike Doustdar of Novo Nordisk acknowledges that despite pioneering the GLP-1 weight loss drug market, analysts have raised concerns about the competitiveness of its pipeline, especially as rival Eli Lilly has surpassed its market share.
- Acquisition Intentions Clear: Doustdar emphasizes that Novo Nordisk is actively seeking acquisition opportunities that complement its existing assets to secure its leadership position in the global obesity drug market, with expectations of more deals to come in the near future.
- Pipeline Outlook Optimistic: He highlights that the CagriSema drug candidate is expected to gain approval by the end of the year, while the accelerated development of the zenagamtide drug also shows promising prospects, reflecting the company's confidence in its new drug development efforts.
- Profit Guidance Raised: Following better-than-expected performance of the Wegovy pill in Q1, Novo Nordisk has raised its full-year profit guidance, indicating a positive outlook for future performance and further solidifying its competitive stance in the market.
See More
Eli Lilly Reports Skyrocketing Q1 Profits Driven by GLP-1 Sales
- Revenue Surge: Eli Lilly's Q1 revenue soared 56% year-over-year to $19.8 billion, primarily driven by its blockbuster GLP-1 weight loss drugs, demonstrating robust market demand despite a 13% price decline offset by a 65% volume increase.
- Net Income Spike: Adjusted net income skyrocketed 155% to $7.7 billion, translating to $8.55 per share, significantly surpassing Wall Street's estimate of $6.79, reflecting the company's strong performance in the weight loss drug sector.
- Sales Growth Drivers: Sales of GLP-1 drugs Mounjaro and Zepbound surged 125% and 80%, reaching $8.7 billion and $4.2 billion respectively, becoming key growth drivers that further solidify the company's market leadership.
- Optimistic Outlook: Eli Lilly raised its 2023 revenue and adjusted EPS guidance to $82 billion to $85 billion and $35.50 to $37, indicating confidence in future growth, particularly with the newly launched GLP-1 pill Foundayo expected to expand market share.
See More
Health Canada Approves Lilly's Kisunla™ (Donanemab) as a New Treatment for Early Alzheimer's Disease
Health Canada Authorization: Health Canada has authorized the use of Lilly's drug, known as Skysunla (donanemab), for the treatment of early Alzheimer's disease.
New Treatment Option: This approval introduces a new therapeutic option aimed at addressing the needs of patients diagnosed with early-stage Alzheimer's.
See More
ELI LILLY SUBMITS SEC FILING FOR EIGHT-PART NOTES OFFERING WORTH UP TO $9 BILLION
- Company Filing: Eli Lilly has filed for an offering of up to $9 billion in senior notes.
- Purpose of Offering: The proceeds from this offering are intended for general corporate purposes.
See More
Eli Lilly Invests $4.5 Billion in Indiana for Advanced Therapies
- Facility Opening: Eli Lilly opened the Lilly Lebanon Advanced Therapies center in Indiana on Wednesday, focusing on genetic disease treatments, which is expected to significantly enhance its production capabilities in genetic medicine.
- Increased Capital Investment: The company announced an additional investment of $4.5 billion for the new facility, bringing its total investment in Indiana to $21 billion since 2020, reflecting strong confidence in future drug demand.
- API Production Plans: Lilly plans to open the Lilly Lebanon API facility by 2027, which will become the largest active pharmaceutical ingredient production site in U.S. history, further solidifying its leadership in the pharmaceutical industry.
- Positive Market Reaction: Despite LLY stock being down nearly 8% this year, it has risen about 28% over the past 12 months, with retail investors expressing an 'extremely bullish' sentiment, indicating market recognition of its investment strategy.
See More
Novo Nordisk CEO: Seeking More Deals to Broaden Pipeline
- Active Business Development: Novo Nordisk CEO Mike Doustdar stated that the company is actively seeking deals with other firms that have complementary assets to fulfill its ambition of helping hundreds of millions of patients, demonstrating its strategic commitment in the competitive obesity drug market.
- Market Competition Pressure: Although Novo Nordisk pioneered the GLP-1 weight loss drug market, rival Eli Lilly has surpassed it in market share for weekly GLP-1 injections, highlighting the challenges the company faces in maintaining its leadership position.
- Optimistic Pipeline Outlook: Doustdar expressed optimism about upcoming treatments, particularly mentioning CagriSema and zenagamtide, which are expected to receive approval by the end of the year, indicating Novo Nordisk's strong R&D capabilities within the industry.
- Increased Profit Guidance: Following better-than-expected performance of the Wegovy pill, Novo Nordisk raised its full-year profit guidance, reflecting the company's confidence in future performance, which may attract more investor interest.
See More
Novo Nordisk Actively Pursuing Acquisition Opportunities
- Market Leadership Challenges: CEO Mike Doustdar of Novo Nordisk acknowledges that despite pioneering the GLP-1 weight loss drug market, analysts have raised concerns about the competitiveness of its pipeline, especially as rival Eli Lilly has surpassed its market share.
- Acquisition Intentions Clear: Doustdar emphasizes that Novo Nordisk is actively seeking acquisition opportunities that complement its existing assets to secure its leadership position in the global obesity drug market, with expectations of more deals to come in the near future.
- Pipeline Outlook Optimistic: He highlights that the CagriSema drug candidate is expected to gain approval by the end of the year, while the accelerated development of the zenagamtide drug also shows promising prospects, reflecting the company's confidence in its new drug development efforts.
- Profit Guidance Raised: Following better-than-expected performance of the Wegovy pill in Q1, Novo Nordisk has raised its full-year profit guidance, indicating a positive outlook for future performance and further solidifying its competitive stance in the market.
See More
